Replimune Group, Inc. - Common Stock (REPL)
14.25
0.00 (0.00%)
Replimune Group Inc is a biotechnology company focused on developing innovative therapies for cancer treatment using its proprietary oncolytic virus platform
By harnessing genetically engineered viruses that selectively target and destroy cancer cells while stimulating the body’s immune system, Replimune aims to revolutionize the approach to cancer care. The company's research and development efforts are centered on creating novel therapeutic options that can potentially provide more effective and less toxic alternatives to traditional cancer treatments. Through their commitment to scientific advancement, Replimune is poised to make significant contributions to the field of oncology.
Frequently Asked Questions
Is Replimune Group, Inc. - Common Stock publicly traded?
Yes, Replimune Group, Inc. - Common Stock is publicly traded.
What exchange does Replimune Group, Inc. - Common Stock trade on?
Replimune Group, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Replimune Group, Inc. - Common Stock?
The ticker symbol for Replimune Group, Inc. - Common Stock is REPL on the Nasdaq Stock Market
What is the current price of Replimune Group, Inc. - Common Stock?
The current price of Replimune Group, Inc. - Common Stock is 14.25
When was Replimune Group, Inc. - Common Stock last traded?
The last trade of Replimune Group, Inc. - Common Stock was at 4:00 pm EST on February 5th, 2025
What is the market capitalization of Replimune Group, Inc. - Common Stock?
The market capitalization of Replimune Group, Inc. - Common Stock is 666.50M
How many shares of Replimune Group, Inc. - Common Stock are outstanding?
Replimune Group, Inc. - Common Stock has 46.77M shares outstanding.